Cytokine signaling generally occurs through receptors lacking tyrosine kinase activity. Aggregation of receptors leads to activation of receptor associated Janus kinases (Jaks) which in turn phosphorylate members of a family of transcription factors (STATs) that translocate to the nucleus and regulate gene expression. In the case of Interleukin-6 (IL-6), the consensus for signaling in B lineage cells has been that Jak1, Jak2 and Tyk2 are all phosphorylated upon ligand binding and participate in activation of downstream elements, in particular STAT3. In other cell types, Jak1 has been demonstrated to be absolutely required for IL-6 mediated activation of STAT3. In the present studies, we have identified a series of end stage B cell (plasma cell) lines that fail to express Jak1, but phosphorylate STAT3 in response to IL-6. No evidence was found for a requirement of other Jak family members in the activation of STAT3. STAT3 tyrosine phosphorylation was inhibited in a dose dependent manner by the MEK inhibitor U0126, but not by inhibitors of PI-3K or Src kinases. Moreover, STAT3 phosphorylation was similarly inhibited in lines expressing Jak1 wherein Jak1 was phosphorylated upon IL-6 stimulation and Jak1 phosphorylation was not inhibited by U0126. These results indicate that the MAPK pathway plays a critical role in IL-6 mediated tyrosine phosphorylation of STAT3 and suggests that Jak kinases may not be required in this cascade. Thus, it may be important to re-evaluate the role of Jak kinases in other cytokine signaling pathways as well.
Cytokine signaling generally occurs through receptors lacking tyrosine kinase activity. Aggregation of receptors leads to activation of receptor associated Janus kinases (Jaks) which in turn phosphorylate members of a family of transcription factors (STATs) that translocate to the nucleus and regulate gene expression. In the case of Interleukin-6 (IL-6), the consensus for signaling in B lineage cells has been that Jak1, Jak2 and Tyk2 are all phosphorylated upon ligand binding and participate in activation of downstream elements, in particular STAT3. In other cell types, Jak1 has been demonstrated to be absolutely required for IL-6 mediated activation of STAT3. In the present studies, we have identified a series of end stage B cell (plasma cell) lines that fail to express Jak1, but phosphorylate STAT3 in response to . No evidence was found for a requirement of other Jak family members in the activation of STAT3. STAT3 tyrosine phosphorylation was inhibited in a dose dependent manner by the MEK inhibitor U0126, but not by inhibitors of PI-3K or Src kinases. Moreover, STAT3 phosphorylation was similarly inhibited in lines expressing Jak1 wherein Jak1 was phosphorylated upon IL-6 stimulation and Jak1 phosphorylation was not inhibited by U0126. These results indicate that the
Introduction
The study of cytokine signaling has, over the past several years, led to major advances in our understanding of the process by which this class of extracellular ligands effects a variety of cellular functions and responses. Significant discoveries in this area include the identification of families of signaling molecules such as Janus (Jak) kinases and signal transducers and activators of transcription (STATs) which associate with a variety of cytokine receptors and initiate signaling cascades (Leonard and O'Shea, 1998; Rane and Reddy, 2000; Gadina et al., 2001) . The complexity of this signaling is striking in that the same cytokine may activate different components in different cell types (Stahl et al., 1994) or diverse cytokines may employ the same or largely overlapping components (Ihle, 1995) . Aggregation of receptors due to ligand binding has, in general, been found to be a major mechanism by which associated Jak kinases are brought into proximity resulting in activation of the kinase domain of these molecules. Activation leads to tyrosine phosphorylation of the kinases themselves, associated receptors and members of the STAT family which then dimerize and translocate to the nucleus where they function as transcription factors (Bromberg and Darnell, 2000; Nosaka and Kitamura, 2000) .
Interleukin-6 (IL-6) is a ubiquitous member of the cytokine family which is involved in a broad spectrum of biological responses (Hirano, 1998) . One of these responses effects the growth and development of B lineage lymphoid cells. IL-6 is important in the terminal differentiation of B cells to antibody secreting plasma cells (Kopf et al., 1994; Hirano et al., 2000) and is suggested to be critical for the development of plasma cell neoplasia (Hilbert et al., 1995; Treon and Anderson, 1998) . IL-6 has been demonstrated to activate both the Jak/STAT and MAPK pathways in these cells (Daeipour et al., 1993; Kumar et al., 1994; Ogata et al., 1997) . Previous studies have indicated that Jak1, Jak2 and Tyk2 are all phosphorylated following IL-6 stimulation leading to tyrosine phosphorylation/activation of primarily STAT3 (Lutticken et al., 1994; Narazaki et al., 1994) . It has also been found in fibrosarcoma cells that Jak1 is absolutely required for IL-6 mediated phosphorylation of STAT3 (Guschin et al., 1995) . Given these findings, it was surprising that we identified a series of plasma cell lines that failed to express Jak1 protein.
Herein, we describe studies indicating that plasma cells do not require Jak kinases for activation of STAT3 and that STAT3 tyrosine phosphorylation likely occurs by an alternative mechanism.
Results

IL-6 mediated phosphorylation of STAT3 in the absence of Jak1
Jak1, Jak2, and Tyk2 have all been suggested to be involved in the IL-6 induced activation of STAT3 in B lineage cells (Berger et al., 1994) . The pattern of Jak kinase activation by IL-6 varies in other cell types, but Jak1 has been demonstrated to be required for STAT3 phosphorylation (Stahl et al., 1994; Guschin et al., 1995) . In the present studies we initially surveyed a series of plasma cell lines for the expression of Jaks implicated in IL-6 signaling. Reverse transcription (RT) -PCR analysis of six such cell lines, as well as the B9 hybridoma, surprisingly revealed an absence of Jak1 m-RNA in three (S107, J558, 8.36) of the plasma cell lines examined after 35 -40 cycles of amplification ( Figure 1a ). Similar RT -PCR analysis for Jak2 and Tyk2 demonstrated ubiquitous and roughly equivalent expression in all lines. Subsequent Western analysis of cell extracts confirmed and extended RT -PCR results ( Figure  1b) , revealing an absence of Jak1 protein in the three lines lacking Jak1 m-RNA, but also a lack of protein expression in two additional lines (X24 and 1165) both of which express Jak1 m-RNA. The only lines expressing Jak1 protein were BPC4 and B9. BPC4 is the single plasma cell line not of BALB/c origin and B9 is a hybridoma thus representing an earlier stage of B cell differentiation. In contrast, all lines expressed Tyk2, Jak2 (see below) and STAT3 proteins as detected by Western analysis. Since STAT3 phosphorylation is a critical step in induction of IL-6 mediated biological effects, we next determined whether IL-6 induced STAT3 tyrosine phosphorylation following IL-6 stimulation of Jak1 negative plasma cell lines. As seen in Figure 1c , IL-6 treatment triggered tyrosine phosphorylation of STAT3 in X24, 1165 and 8.36 cells in the absence of detectable Jak1 protein. The S107 cell line produces functional IL-6 and thus serum starvation does not effect high levels of constitutive STAT3 tyrosine phosphorylation. Taken together, these results reveal that all BALB/c plasma cell lines are defective in Jak1 protein expression, but that STAT3 can be tyrosine phosphorylated following IL-6 stimulation in the absence of this member of the Janus kinase family.
Transfected wild type Jak1 is functional in Jak1 negative plasma cell lines and restores IFNa-induced tyrosine phosphorylation of STAT3
The question of whether Jak1 is functional and/or necessary for signaling in murine plasma cells was next addressed by examination of the IFNa response. Phosphorylation of STAT1 and STAT3 following IFNa stimulation was profoundly inhibited in plasma cells lacking Jak1 protein (not shown). We, therefore, introduced wild type Jak1 cDNA by retroviral transfection into X24 cells that lack Jak1 protein. Cultures derived from transfected, G418 resistant X24 clones and parental cells were used in experiments to assess the responses to IFNa and IL-6 stimulation ( Figure 2 ). As expected, in parental X24 cells STAT3 was not phosphorylated on tyrosine-705 in response to IFNa treatment. Following transfection of Jak1, phosphorylation of this residue was readily induced. However, Jak1 transfected X24 cells showed no increase in STAT3 tyrosine phosphorylation following IL-6 stimulation. Similar results were observed in Jak1 reconstituted 8.36 cells (data not shown). These findings demonstrate that wild type Jak1 is functional in plasma cells and required for phosphorylation of STAT3 by IFNa, but not IL-6. RT -PCR analysis for RNA expression of Jak kinases in murine plasmacytoma cell lines. Total RNA was isolated from the indicated cell lines, reverse transcribed and cDNA's were added to PCR reactions containing primers specific for Jak1, Jak2, Tyk2 and b-actin. PCR samples were subjected to 36 (Jak kinases) or 28 (b-actin) cycles of amplification. (b) Analysis of Jak1 protein expression in murine plasmacytomas. Immunoprecipitation was performed using 1 mg of total extracted protein from the indicated lines with antibody to Jak1 followed by blotting with the same antibody (upper panel). The same lysates were subjected to direct Western analysis with anti-Tyk2 and anti-STAT3 (lower panels). (c) Tyrosine phosphorylation of STAT3 in response to IL-6 in plasmacytoma cell lines lacking Jak1 protein. Serumstarved S107, X24, 1165 and 8.36 cells were treated with IL-6 (10 ng/ml) for 15 min. Cell lysates were immunoprecipitated with anti-STAT3 and blotted with anti-phosphotyrosine (4G10) antibodies. The membrane was then stripped and re-analysed with anti-STAT3 IL-6 does not activate Jak2 and phosphorylation of Tyk2 is not sufficient for activation of STAT3
Since Jak1 was found not to be involved in IL-6 mediated STAT3 phosphorylation, the possibility was considered that Jak2 and/or Tyk2 might provide this function. Immunoprecipitation studies with anti-sera recognizing Jak2 followed by Western analysis with 4G10 antiphosphotyrosine antibody revealed no phosphorylation of Jak2 in either cells pulsed with, or grown in the continuous presence of, IL-6 (Figure 3a) . Similar negative results were obtained in studies of Jak3 (not shown). The failure of Jak2 to participate in STAT3 phosphorylation was confirmed by use of the Jak2 inhibitor tyrophostin AG490 (Meydan et al., 1996) . Following 4 -6 h of exposure to 50 or 100 mM AG490, 8.36 cells were stimulated with IL-6 and analysed for STAT3 tyrosine phosphorylation (Figure 3b ). Pretreatment with AG490 did not inhibit tyrosine phosphorylation of STAT3 in response to IL-6. In control experiments with human IL-6 dependent multiple myeloma cell line XG2 (De Vos et al., 2000) using the same conditions of AG490 treatment, IL-6 induced Jak2 tyrosine phosphorylation was inhibited by 50 mM AG490 (data not shown). It should be noted that with extended exposure to AG490 for more than 12 h, 8.36 cells displayed intensive cell death. Interestingly, pretreatment with AG490 did not inhibit Tyk2 phosphorylation in 8.36 cells after IL-6 stimulation ( Figure 3c) .
In contrast to Jak2, a significant increase in the tyrosine phosphorylation of Tyk2 protein was observed upon IL-6 stimulation ( Figure 4a ). Phosphorylation of Tyk2 was primarily associated with the upper band of the doublet observed in most lines. To examine the potential contribution of Tyk2 to STAT3 tyrosine phosphorylation, we employed wild type and kinasedeficient mutant (K 930 I) Tyk2 (Krishnan et al., 1997) stable transfectants of X24 and 8.36 cells. Overexpression of wild type Tyk2 led to high levels of auto-phosphorylation (not shown) as well as constitutive tyrosine phosphorylation of STAT3 (Figure 4b ). Tyrosine phosphorylation of STAT3 was increased in the presence of IL-6. Over-expression of mutant Tyk2 resulted in STAT3 tyrosine phosphorylation that was not decreased beyond the vector control. This result suggested that mutant K 930 I Tyk2 protein had no effect on STAT3 tyrosine phosphorylation following IL-6 treatment. Identical results were obtained with wild type and K 930 I Tyk2 transfected 8.36 cells (data not shown). It should also be noted that no change was observed in phosphorylation of STAT3 ser-727 in this, or any other experiments, in contrast to the reported induced phosphorylation of this residue by IL-6 in HepG2 cells (Chung et al., 1997; Schuringa et al., 2000) . The failure of dominant negative Tyk2 to effect STAT3 tyrosine phosphorylation taken together with the observation that cells from Tyk2 knockout mice have no impaired IL-6 signaling (Karaghiosoff et al., 2000) , strongly suggest that Tyk2 does not play a critical role in IL-6 signaling. Furthermore (see below), STAT3 phosphorylation can be completely inhibited in Figure 2 Wild type Jak1 is functional in murine plasmacytomas and required for IFNa-induced tyrosine phosphorylation of STAT3, but not for tyrosine phosphorylation of STAT3 following IL-6 stimulation. Parental X24 and X24-Jak1 transfected cells were serum-starved for 4 h followed by treatment with IFNa (200 U/ml) or IL-6 (10 ng/ml) for 15 min as indicated. Cell lysates were subjected to Western analysis using antibodies to Jak1 and pTyr(705)STAT3. The membrane was stripped and reanalysed with anti-STAT3 Figure 3 Activation of Jak2 is not required for tyrosine phosphorylation of STAT3 following IL-6 stimulation. (a) S107, X24, 8.36 and 1165 cells were either serum-starved (ST), treated with IL-6 (10 ng/ml) for 15 min (IL-6) or maintained un-starved in the continued presence of IL-6 (UST). Cell lysates (1 mg of total protein for each cell line) were immunoprecipitated with antiJak2 and Western analysis was carried out with anti-phosphotyrosine (4G10) antibodies. The membrane was then stripped and reanalysed with anti-Jak2. (b) Serum-starved 8.36 cells were pretreated with solvent (D, dimethylsulphoxide) or AG490 at the concentrations indicated for 4 h and then stimulated with IL-6 (10 ng/ml) for 15 min. Serum-starved untreated cells were used as controls. Cell lysates were immunoprecipitated with anti-STAT3 and blotted with anti-phosphotyrosine (PY99) antibodies. The membranes were then stripped and re-analysed with anti-STAT3. (c) Serum-starved 8.36 cells were pretreated with solvent (D, dimethylsulphoxide) or AG490 (100 mM) for 4 h and then stimulated with IL-6 (10 ng/ml) for 15 min. Lysates from 8.36 cells were prepared and subjected to Western analysis using antibodies to pTyr(1054/1055)Tyk2. The membranes were then stripped and re-analysed with anti-Tyk2 the presence of normal Tyk2 phosphorylation induced by either IL-6 or IFNa.
Treatment of plasma cells with MEK inhibitor U0126 abolishes IL-6-induced tyrosine phosphorylation of STAT3
Having demonstrated that Jak kinases are not required for phosphorylation of STAT3, we next examined a series of metabolic inhibitors known to block specific cellular pathways. Treatment with the PI-3K inhibitor Wortmannin (Ui et al., 1995) or the Src inhibitor PP2 (Hanke et al., 1996) had no effect on IL-6 mediated tyrosine phosphorylation of STAT3 (data not shown). However, similar treatment with the MEK inhibitor U0126 (Favata et al., 1998) resulted in a dose dependent inhibition of STAT3 phosphorylation in three lines (1165, 5.25 and S107) and inhibition in a fourth (X24) at the highest concentration tested (Figure 5a ). Inhibition of STAT3 phosphorylation was not a result of cell toxicity since treatment with U0126 did not increase the fraction of cells stained with Trypan blue (data not shown). IL-6 has previously been reported to activate the MAPK pathway leading to proliferation of plasma cells (Daeipour et al., 1993; Kumar et al., 1994) . Thus, to verify the effect of U0126 we performed both cell proliferation (Figure 5b ) and kinase inhibition assays (Figure 5c ). Cell proliferation was inhibited in a dose dependent manner and MAPK activity was inhibited at all concentrations tested. All murine lines examined had readily detectable levels of endogenous MAPK activity under the starvation conditions employed and both this basal level and the IL-6 induced increase were effectively inhibited. In similar experiments using a second MEK inhibitor, PD098059 (Alessi et al., 1995) , we were not able to achieve effective inhibition of MEK activity in IL-6 treated plasma cells (8.36 and X24) at the highest tested concentration (100 mM). This result is consistent with data indicating PD098059 is a far weaker MEK1/2 inhibitor than U0126 (Favata et al., 1998) and primarily inhibits MEK1. The magnitude of the MAPK response to IL-6 likely precludes the possibility of PD098059 inhibition at concentrations that are not toxic.
To determine whether the observed inhibition of STAT3 phosphorylation by U0126 might be species related, similar experiments were performed using the human multiple myeloma lines OPM-2 and Delta47. As can be seen (Figure 6a,b) , U0126 again inhibited STAT3 tyrosine phosphorylation in a dose dependent manner in IL-6 stimulated OPM-2 and Delta47 cells. Identical results were obtained with a third human myeloma line, ANBL-6 (data not shown). It is important to note that in the Delta47 line Jak1 is also phosphorylated in response to IL-6, but this phosphorylation is not affected by the inhibitor. Analysis of Tyk2 (not shown) similarly revealed no inhibition of Tyk2 phosphorylation. IL-6 strongly induced MAPK activity that peaks at approximately the same time as STAT3 phosphorylation (not shown) and is readily inhibited by U0126 (Figure 6c ). To further investigate the role of MEK1/2 activity in STAT3 tyrosine phosphorylation, we examined STAT3 phosphorylation in IFNa stimulated Delta47 cells after treatment with U0126 ( Figure 7 ). Pre-incubation with U0126 prior to IFNa treatment resulted in concentration dependent inhibition of STAT3 tyrosine phosphorylation (Figure 7a ). Additionally, analysis of Jak kinase activation showed that IFNa induced Jak1 and Tyk2 tyrosine phosphorylation was not affected by U0126 treatment (Figure 7b ). These results indicate that inhibition of STAT3 tyrosine phosphorylation by U0126 is independent of Jak1 and Tyk2 activities. Taken together, the U0126 data demonstrate that IL-6 and IFNa induced STAT3 tyrosine phosphorylation is a MEK1/2 dependent process, at least in plasma cell lines, and down regulation of MEK1/2 activity with a pharmacological agent reduces STAT3 tyrosine phosphorylation in a Jak independent manner. Discussion IL-6 is a pleotropic cytokine required for regulation of cell growth, differentiation and survival (Hirano, 1998). STAT3 protein plays a central role in transmitting IL-6 signals from the membrane into the nucleus of responsive cells (Bromberg and Darnell, 2000; Nosaka and Kitamura, 2000) . Binding of IL-6 to its cellular receptor leads to the specific assocation of STAT3 with the gp130 subunit of the receptor complex and critical phosphorylation of tyrosine-705 in STAT3 molecules. Following tyrosine phosphorylation, STAT3 proteins form homodimers or heterodimers with STAT1 and move into the nucleus, where they regulate the expression of specific sets of genes. The three known members of the Jak kinase family (Jak1, Jak2 and Tyk2) are constitutively associated with the gp130 subunit and their activation in response to IL-6 coincides with critical tyrosine phosphorylation of STAT3 molecules. Jak1, Jak2 and Tyk2 become phosphorylated and activated following treatment with IL-6, but the pattern of Jak phosphorylation varies with different cell types (Stahl et al., 1994) . Studies with mutant human fibrosarcoma cell lines lacking various Jaks indicated that activation of Jak1 was critical for STAT3 tyrosine phosphorylation and IL-6 signaling (Guschin et al., 1995) . The results from Jak2 and Tyk2 deficient cells and kinase knockout models have led to the conclusion that Jak2 and Tyk2 activities are not required for STAT3 tyrosine phosphorylation following IL-6 stimulation (Guschin et al., 1995; Parganas et al., 1998; Karaghiosoff et al., 2000) . Based on this data, it has been assumed that Jak1 is the critical element for IL-6 signaling through STAT3. Our results demonstrate that in mouse plasmacytoma cells Jak1 protein is not required for the tyrosine phosphorylation of STAT3 in response to IL-6. In the present studies, we observed that BALB/c plasmacytoma cell lines are defective in Jak1 mRNA and/or protein expression (Figure 1 ). Western analysis revealed absence of Jak1 protein in five cell lines, and RT -PCR demonstrated an absence of Jak1 mRNA in three of these. However, IL-6 treatment induced strong STAT3 tyrosine phosphorylation in all of these lines. A potentially functional role for Jak1 in these cells was demonstrated following transfection of wild type Jak1 cDNA. Jak1 protein expression leads to a restored Jak1-dependent IFNa response (Figure 2) . In tested plasmacytoma cell lines lacking Jak1, neither STAT3 or STAT1 (data not shown) become tyrosine phosphorylated following treatment with IFNa. IFNainduced tyrosine phosphorylation of STAT3 was restored upon reconstitution of the plasmacytoma cells with Jak1. However, analysis of IL-6 signaling in Jak1 transfected plasmacytoma cells revealed that expression of wild type Jak1 protein does not change the pattern of STAT3 tyrosine phosphorylation. This observation further supports the conclusion that Jak1 activation does not play a critical role in IL-6 signaling in plasma cells.
In several cell lines, it has been reported that Jak2 becomes phosphorylated and activated following treatment with IL-6 (Narazaki et al., 1994) . However, we failed to detect any tyrosine phosphorylation of Jak2 in plasmacytoma cells after IL-6 stimulation ( Figure 3) . Absence of Jak2 phosphorylation does not rule out the possibility that non-phosphorylated Jak2 may contribute to STAT3 phosphorylation in response to IL-6, Figure 6 U0126 inhibits STAT3 tyrosine phosphorylation in human OPM-2 and Delta47 cells and does not affect Jak1 phosphorylation in response to IL-6. (a) Serum-starved OPM-2 cells were pretreated with solvent (D, dimethylsulphoxide) or U0126 at concentrations indicated for 1 h and then stimulated with human IL-6 for 15 min. Serum-starved, untreated cells were used as controls. Cell lysates were immunoprecipitated with anti-STAT3. Eluted proteins were separated by 8% SDS -PAGE and Western analysis was carried out with anti-phosphotyrosine (PY99) antibodies. The membranes were then stripped and analysed with anti-STAT3. (b) Lysates from Delts47 cells prepared as in (a) were immunoprecipitated with anti-STAT3 and antiJak1. Eluted proteins were separated by 8% SDS -PAGE and Western analysis was carried out with anti-phosphotyrosine (PY99) antibodies. The membranes were then stripped and analysed with anti-STAT3 and anti-Jak1 to control for loading. (c) MAPK activity was determined on lysates prepared as in (a). Cell lysates were immunoprecipitated with anti-phospho-p44/42 MAPK antibody and kinase assays were performed using Elk-1 as a substrate. Phosphorylated Elk-1 protein was detected by Western analysis with anti-pSer(383)Elk-1 antibody Figure 7 U0126 inhibits INFa induced STAT3 tyrosine phosphorylation in human Delta47 cells, but does not affect Tyk2 or Jak1 phosphorylation. (a) Serum-starved Delta47 cells were pretreated with solvent (D, dimethylsulphoxide) or U0126 at concentrations indicated for 1 h and then stimulated with human IFNa (200 U/ml) for 15 min. Serum-starved, untreated cells were used as controls. Cell lysates were subjected to Western analysis using antibodies to pTyr(705)STAT3. The membranes were then stripped and re-analysed with anti-STAT3. (b) Cells were prepared as in (a) and lysates were subjected to Western analysis using antibodies to pTyr(1054/1055)Tyk2. The membranes were then stripped and re-analysed with anti-Tyk2. Cell lysates were also immunoprecipitated with anti-Jak1. Eluted proteins were separated by 8% SDS -PAGE and Western analysis was carried out with anti-phosphotyrosine (PY99) and anti-Jak1. (c) MAPK activity was determined on lysates prepared as in (a). Cell lysates were immunoprecipitated with anti-phospho-p44/42 MAPK antibody and kinase assays were performed using Elk-1 as a substrate. Phosphorylated Elk-1 protein was detected by Western analysis with anti-pSer(383)Elk-1 antibody but such a role would seem unlikely, at least in the current view of Jak/STAT signaling. Furthermore, the Jak2 kinase inhibitor tyrophostin AG490 did not effect STAT3 tyrosine phosphorylation following IL-6 treatment. In contrast to Jak2, Tyk2 protein was tyrosine phosphorylated in plasmacytoma cells following IL-6 stimulation. To assess a potential role for Tyk2 in STAT3 phosphorylation, we generated stably transfected plasmacytoma cells expressing a dominant negative (K 930 I) Tyk2 (Krishnan et al., 1997) . Expression of mutant K 930 I Tyk2 protein had no effect on STAT3 tyrosine phosphorylation following IL-6 treatment of X24 cells. It should be noted that over expression of wild type Tyk2 leads to auto-phosphorylation and IL-6 independent STAT3 phosphorylation. This observation points out the danger of over expression studies in attempting to identify true physiological participation in signaling processes. Furthermore, it has been demonstrated that Tyk2 knock out mice have normal responses to IL-6 (Karaghiosoff et al., 2000) . Taken together, these results indicate that Tyk2 activation is not essential for IL-6 mediated STAT3 signaling. In summary, the above experiments demonstrate that, in plasma cells, Jak kinase activation is not required for tyrosine phosphorylation of STAT3 and, thus, STAT3 phosphorylation likely occurs by an alternate mechanism.
In addition to STAT activation, IL-6 binding has also been shown to trigger the Ras/MAPK signaling pathway (Daeipour et al., 1993; Kumar et al., 1994; Ogata et al., 1997) . Therefore, as one potential mechanism for STAT activation, we examined the MAPK pathway in relation to STAT3 tyrosine phosphorylation. In the present studies, we observed that the MEK inhibitor U0126 abrogated plasmacytoma cell proliferation at low concentrations and repressed STAT3 tyrosine phosphorylation in a dose dependent manner ( Figure 5 ). Since these lines do not express Jak1, and Jak2 is not phosphorylated following IL-6 treatment, this observation further excludes a Jak1 and/or Jak2 mediated MEK-dependent mechanism of STAT3 tyrosine phosphorylation. To ascertain whether MEK dependent STAT3 phosphorylation might be limited to murine plasma cells, similar experiments were performed using human myeloma lines (Figure 6 ). Identical results were obtained demonstrating inhibition of STAT3 tyrosine phosphorylation with increasing concentrations of MEK inhibitor. As these human lines express functional Jak1 protein, we were able to further demonstrate that U0126 treatment does not effect IL-6 inducible Jak1 or Tyk2 phosphorylation while, at the same time, inhibiting STAT3 phosphorylation. It should also be noted that the MEK dependent phosphorylation of STAT3 demonstrates specificity, as U0126 does not inhibit IL-4 dependent phosphorylation of STAT6 (Heller and Rudikoff, unpublished data). Furthermore, experiments with IFNa stimulation of human Jak1-expressing myeloma cells demonstrated that, as in the case of IL-6, U0126 inhibited STAT3 tyrosine phosphorylation while having no effect on phosphorylation of Jak1 or Tyk2 (Figure 7) . Neither the PI-3K inhibitor Wortmannin nor the Src inhibitor PP2 had any effect on STAT3 tyrosine phosphorylation. Thus, the data presented indicate that STAT3 tyrosine phosphorylation may be MEK dependent and may not involve Jak kinases in some cell types.
A role for the MAPK kinase pathway in STAT regulation has been suggested by previous studies, but conflicting results have been described. In several systems tyrosine phosphorylation and transcriptional activity of STAT proteins have been reported to be potentiated by activation of the Ras/MAPK pathway (Eilers et al., 1995; Zhang et al., 1995) . More recently, activation of extracellular signal-regulated kinases (ERKs) in the MAPK pathway has been reported to reduce STAT3 phosphorylation. Chung et al. (1997) have shown that serine phosphorylation of STAT3 at position 727 by an ERK-dependent pathway negatively modulated subsequent STAT3 tyrosine phosphorylation at Tyr-705. Similarly, Sengupta et al. (1998) reported that PMA triggered ERK activation inhibited IL-6-induced Jak-STAT signaling in CHO and 293T cells. These authors suggested that inhibition of STAT3 tyrosine phosphorylation occurs at the level of the IL-6 receptor complex and involves ERK-dependent down regulation of Jak1 and Jak2 phosphorylation following IL-6 stimulation. The present results in plasma cells clearly are not consistent with an inhibitory effect of MEK activation and, moreover, demonstrate that MEK activity is essential for IL-6 induced STAT3 tyrosine phosphorylation in plasma cells. It should be noted that no changes were detected in the level of STAT3 serine-727 phosphorylation following IL-6 stimulation in the present studies. This observation excludes the likelihood of inhibitory effects of STAT3 serine-727 phosphorylation on tyrosine-705 phosphorylation.
The conflicting results described above may be explained in several ways. It is possible that different cell types employ diverse mechanisms for regulation of STAT3 tyrosine phosphorylation by IL-6. Thus, while Jak kinases may be required for STAT3 phosphorylation in some cell types, others, such as plasma cells, may employ alternative and/or parallel pathways. Furthermore, the fact that Jak kinases are phosphorylated following ligand binding, may not indicate a necessary role in subsequent STAT phosphorylation. This may also be true in the case of signaling by other cytokines and should be carefully evaluated. Alternatively, the same pathway may provide both positive and negative regulatory effects depending on factors such as the degree of activation or the stage of cell differentiation. Thus, for example, the MAPK kinase pathway may perform both roles in the same cell type. As reported in CHO and 293T cells (Sengupta et al., 1998) , we observed (not shown) that over-expression of constitutively activated MEK1 (S218D/S222D) in plasma cells leads to a significant reduction in IL-6 mediated STAT3 phosphorylation. It is conceivable that the MAPK pathway participates in both positive and negative regulation through complex interactions with other pathways not presently understood. Such interactions may contribute to the ultimate decision as to whether regulation will be positive or negative. Regardless of the specific mechanisms involved, the above discussion points out the likely critical importance of cell lineage in pathway usage and the danger in generalizing signaling pathways among differing cell types.
Given the result of STAT3 phosphorylation without a Jak kinase requirement, the question remains as to the kinase that actually phosphorylates STAT3. We were unable to detect MEK proteins in complexes with STAT3 either by direct co-precipitation or by using antibodies to other proteins with which either of these two have been reported to associate. We have also examined a number of other cellular kinases either previously reported to associate with the IL-6 receptor or to be expressed in B lineage cells as candidates for the STAT3 kinase (Matsuda et al., 1995a,b; Hallek et al., 1997) . Fyn, Lyn and Blk were expressed in all lines, constitutively phosphorylated, and showed no changes in response to IL-6. Hck and Tec kinases were observed in some lines and were similarly constitutively phosphorylated. Syk and Vav were present in most lines, but not phosphorylated and unchanged following IL-6 treatment. Btk was not detected in these lines. Thus, we have not identified an IL-6 regulated kinase that appears to be a likely candidate. Current studies are aimed at the identification and characterization of this molecule.
Materials and methods
Biological reagents
Murine recombinant IL-6, human recombinant IL-6, murine IFNa and human IFNa were obtained from BRL -GIBCO Life Technologies (Life Technologies, Rockville, MD, USA). U0126 purchased from Cell Signaling Technology (Beverly, MA, USA) was solubilized in DMSO at 20 mM and stored at 7208C protected from light. PD098059 was purchased from Cell Signaling Technology. Jak kinase inhibitor, AG490, was purchased from Calbiochem (La Jolla, CA, USA).
Cell lines and culture
All murine plasmacytoma lines were pristane or oil induced in BALB/c mice with the exception of BPC4 (C57BL/6) and B9 (BALB/c hybridoma). Murine plasmacytoma lines X24, S107, J558, 5.25 and human multiple myeloma Delta47 and OPM-2 cell lines were grown in RPMI 1640 medium supplemented with 10% heat inactivated fetal calf serum, 5610
75 M 2-mercaptoethanol and 10 mg/ml gentamicin. The 8.36, B9, BPC4 and 1165 lines were maintained in the same complete medium with addition of 1 ng/ml of IL-6. Retrovirus transfected plasmacytoma cells were maintained in complete medium with (8.36 derivative cells) or without (X24 derivative cells) addition of IL-6, supplemented with 800 mg/ ml of G418. 3T3 and BOSC-23 cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum and 10 mg/ml gentamicin. Before cytokine treatment plasmacytoma cell lines were incubated in complete medium with 1% fetal calf serum for 3 -4 h to minimize constitutive protein phosphorylation.
Immunoprecipitation and Western blot analysis
Following treatment, cells were washed twice with ice cold PBS and cell pellets lysed for 15 min at 48C in immunoprecipitation buffer containing 100 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.25% sodium deoxycholate, 5 mM sodium pyrophosphate, 10 mM NaF, 1 mM sodium orthovanadate, 1 mM 4-(2-aminoethyl)-benzenesulphonyl fluoride hydrochloride (AEBSF), 10 mg/ml aprotinin, 10 mg/ml antipain, and 10 mg/ml leupeptin. Cellular debris was pelleted by centrifugation at 16 000 g at 48C for 10 min and protein content was quantified using the BCA assay (Pierce, Rockford, IL, USA). Lysates were incubated for 3 h at 48C with anti-Jak1 (Transduction Laboratories, Lexington, KY, USA), anti-Jak2 (HR-758), anti-Tyk2 (C-20) or anti-STAT3 (H-190) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immuno-complexes were collected with Protein A/G Agarose (Santa Cruz Biotechnology) for 1 h. The agarose beads containing immuno-complexes were washed three times with immunoprecipitation buffer and bound proteins were eluted by boiling in electrophoresis SDS-sample buffer containing 2% 2-mercaptoethanol. Eluted proteins or cell extracts were fractionated by electrophoresis in 8 -10% sodium dodecyl sulphate-polyacrylamide gels (SDS -PAGE) and transferred on PVDF Immobilon-P membranes (Millipore Corp., Bedford, MA, USA). Membranes were blocked in PBS, 0.1% Tween 20 and 5% bovine serum albumin for 1 h at room temperature. The following antibodies were used for Western blot analysis: anti-Jak1 (Transduction Laboratories); anti-phosphotyrosine (PY99), anti-Jak2 (HR-758), anti-Tyk2 (C-20), anti-STAT3 (H-190) (Santa Cruz Biotechnology); anti-pTyr(705)STAT3, anti-pSer(727)STAT3, anti-pTyr(1054/ 1055)Tyk2, anti-pTyr(701)STAT1 (Cell Signaling); and antiphosphotyrosine 4G10 (Upstate Biotechology). Horseradish peroxidase-coupled goat anti-rabbit or goat anti-mouse immunoglobulin (Transduction Laboratories) was used for visualization using SuperSignal Chemiluminescence Substrate (Pierce). Membranes were stripped by incubating in Restore Western Blot Stripping Buffer (Pierce) at room temperature for 30 min.
Reverse transcription-polymerase chain reaction (RT -PCR) analysis
Total RNA was prepared using an RNA isolation kit (Qiagen, Santa Clara, CA, USA). First-strand cDNA synthesis was performed with an Advantage RT -PCR kit (Clontech, Palo Alto, CA, USA) according to the manufacturer's instructions. Polymerase chain reaction (PCR) was carried out in the presence of 1 mM MgCl 2 , 250 mM dNTPs, 0.2 mM each primer and 2 U of Taq DNA polymerase (Perkin Elmer, Foster City, CA, USA). The forward and reverse PCR primers and the expected size of amplification product are as follows: Jak1, 5'-ATG CTG ACC ACA GAC TCC TTT ATT ACA A-3' and 5'-TAT GAG AAG AAA AGG GTT CCA GAA GCA A-3' (740 bp); Jak2, 5'-TCA CTT TCC TTA TGT TTC CCT CTT GAC C-3' and 5'-AGT GGC AGC AGC AGA ACC TAC AGA TAC G-3' (545 bp); Tyk2, 5'-GCA TCC ACA TCG CAC ACA AAG TCG-3' and 5'-TTC ACC ATC ACA ACC TGC TGG GAG-3' (598 bp). b-Actin primer set for RT -PCR (Stratagene) was used for control of PCR performance and quality of cDNA preparation. Each PCR sample was cycled at 948C for 30 s, 658C for 30 s and 728C for 1 min for 28 -40 cycles, followed by a 5-min final extension at 728C. The products were electrophoresed in 2% agarose gels containing ethidium bromide and photographed.
DNA constructs
Tyk2 wild type (wt) and dominant negative K 930 I Tyk2 plasmids were a generous gift from JJ Krolewski (University of California, Irvine, CA, USA). Wt Tyk2 and mutant K 930 I Tyk2 were subcloned in retrovirus vector pFB-Neo (Stratagene, La Jolla, CA, USA)
To obtain full length Jak1wt cDNA, RT -PCR was employed to produce Jak1 cDNA from total 3T3 cell cDNA. All RT -PCR steps were carried out using the ProStar Ultra HF RT -PCR kit (Stratagene) according to the manufacturer's protocol. The forward and reverse Jak1 PCR primers are as follows: 5'-AAA TCC AGT CTG CTT TCA GGG ACA-3' and 5'-AGG CAT ATC CAC ACA CTG AGT GAC AG-3'. A Pfu DNA polymerase generated 3670 bp Jak1 fragment was cloned into EcoRI digested and T4 DNA polymerase blunted pFB-Neo retrovirus vector.
VSV-G pseudotyped retrovirus preparation and infection of B cells
The resulting pFB-Neo constructs and parental pFB-Neo plasmid were used for packaging cell transfection. In the present experiments, vesicular stomatitis virus G protein (VSV-G) pseudotype retrovirus (Yang et al., 1995) was used because the resulting pseudotyped virus stocks had at least three times higher infectious titers after B cell infection than regular packaged stocks. Four micrograms of retrovirus construct and one microgram of pVPack-VSV-G (Stratagene) plasmid were cotransfected into 10 6 BOSC-23 (Pear et al., 1993) packaging cells using Lipofectamine Plus reagent (Life Technologies, Rockville, MD, USA). After 2 days of culture, the supernatant was collected, passed through 0.45 mm filters, frozen in dry ice and stored at -708C. The infectious titers of retorviral supernatants determined after 3T3 cell infection were in the range 10 5 -10 6 c.f.u./ml. For B cell infection, undiluted retrovirus supernatants supplemented with 4 mg/ml of polybrene (Sigma, St Louis, MO, USA) were added to cell suspensions. After 2 days incubation, infected cells were selected in medium containing 800 mg/ml of G418 over a 2 week period.
MAPK activation assay
Determination of MAPK activity in cell extracts was performed with a non-radioactive p44/42 MAP kinase assay kit (Cell Signaling) according to the manufacturer's instructions. Resulting Elk-1 phosphorylation was detected by Western analysis using anti-pSer(383) Elk-1.
Cell proliferation assay
Plasmacytoma cells were plated in quadruplicate in 96-well plates at 10 4 cells/well in the presence of increasing concentration of U0126. Cells were subsequently incubated for 3 days and then analysed with the use of CellTiter 96 AQ ueous Non-Radioactive Cell Proliferation Assay kit (Promega). Twenty ml/well of freshly prepared combined MTS/PMS solution was added and plates were incubated for 2 h at 378C in a humidified 5% CO 2 atmosphere. Absorbance at 490 nm was read on an ELISA plate reader (Bio-Rad, CA, USA).
